Rimegepant
Treatment for Migraine
Typical Dosage: 75mg oral (acute or every other day for prophylaxis)
Effectiveness
80%
Safety Score
70%
Clinical Trials
45
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
75mg oral (acute or every other day for prophylaxis)
Time to Effect
1-2 hours (acute), 1-2 weeks (prophylaxis)
Treatment Duration
As needed (acute), long-term (prophylaxis)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$12,150
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$300,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$20,250
Prescription Access Economics
Annual Societal Loss per Patient
$6,240
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$200/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$12,000/year
Potential OTC Price
$3,000/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWRimegepant Outcomes
for Migraine
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+60%
Common Side Effects
Nausea
+3%
Abdominal pain
+2%
Somnolence
+1%
Active Clinical Trials
8 active trials recruiting for Rimegepant in Migraine
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832RECRUITING
100 participants
OBSERVATIONAL
Florence, Italy +1 more
Started: Mar 26, 2024
The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China
NCT06728345NOT YET RECRUITING
300 participants
OBSERVATIONAL
Started: Dec 1, 2024
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
NCT06439628ACTIVE NOT RECRUITING
3K participants
OBSERVATIONAL
Beijing, China +2 more
Started: Aug 27, 2024
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
NCT05046613RECRUITING
780 participants
OBSERVATIONAL
Wilmington, United States
Started: Sep 23, 2021
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194ACTIVE NOT RECRUITINGPHASE3
636 participants
INTERVENTIONAL
Phoenix, United States +101 more
Started: Nov 15, 2024
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
NCT07906262ACTIVE NOT RECRUITING
1 participants
OBSERVATIONAL
New York, United States
Started: Oct 12, 2026
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398RECRUITINGPHASE3
640 participants
INTERVENTIONAL
Fort Smith, United States +92 more
Started: Feb 28, 2022
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
NCT07667621RECRUITINGPHASE1
100 participants
INTERVENTIONAL
Tampa, United States
Started: Sep 15, 2026
Completed Clinical Trials
10 completed trials for Rimegepant in Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400COMPLETEDPHASE4
813 participants
INTERVENTIONAL
Los Angeles, United States +92 more
Started: Oct 18, 2022
A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
NCT06221267COMPLETED
120 participants
OBSERVATIONAL
Guangzhou, China
Started: Jan 26, 2024
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865COMPLETEDPHASE4
441 participants
INTERVENTIONAL
Phoenix, United States +18 more
Started: Mar 15, 2022
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
NCT05810038COMPLETEDPHASE3
787 participants
INTERVENTIONAL
Hefei, China +48 more
Started: May 15, 2023
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
NCT05399485COMPLETEDPHASE3
496 participants
INTERVENTIONAL
Matsuyama, Japan +43 more
Started: Aug 9, 2022
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
NCT03732638COMPLETEDPHASE2, PHASE3
1.59K participants
INTERVENTIONAL
Chandler, United States +92 more
Started: Nov 14, 2018
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
NCT06680206COMPLETED
1.4K participants
OBSERVATIONAL
New York, United States
Started: Oct 10, 2024
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123COMPLETEDPHASE4
962 participants
INTERVENTIONAL
Los Angeles, United States +110 more
Started: Nov 7, 2022
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
NCT05399459COMPLETEDPHASE3
897 participants
INTERVENTIONAL
Ichikawa-shi, Japan +49 more
Started: Aug 9, 2022
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
NCT05709106COMPLETED
173 participants
OBSERVATIONAL
Boao, China
Started: Jan 11, 2023
Showing 20 of 56 total trials